MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ABEO Stock advanced +0.22% Today — RQD Quant Desk Flash
$4.56 +0.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.55
Abeona Therapeutics Inc. (ABEO) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $260.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.55 (-0.15%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABEO)Realized 20D OHLCV Swing Band: ±9.9%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY ABEO SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (38% of score)
FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 36.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (31% of score)
20D Institutional Volume Accumulation (±9.9% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.94-10.3% Next Q
47
Q2 (-2Q)Grade D$4.43-0.7% Next Q
44
Q3 (-1Q)Grade D$4.40+3.6% Next Q
42
CurrentGrade D-$4.56-7.6% Hist 90D α
39
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABEO Turnaround Squeeze
While ABEO currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.24) and Max Pain ($4.79) forces dealer call-delta covering toward $8.03.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABEO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABEO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABEO Stock advanced +0.22% Today — RQD Quant Desk Flash
Abeona Therapeutics Inc. (ABEO) advanced +0.22% to $4.56, trading at 15% of its 52-week range ($4 – $7.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($4 – $7.65) with RSI-14 at 36.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.9% around $4.56 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 73.7% gross margin and $0 annual free cash flow.
Live ABEO Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABEO)
- ✓Walkthrough of ABEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.48%📐 HORIZONTAL RANGE
2026-10-30O $4.50H $4.56L $4.31C $4.56VOL 783.0K
RES: $9.01SUP: $3.94SMA50: $5.24SMA200: $5.49
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ABEO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABEO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABEO)
Health Care Rank #673 of 1016
⚔️ IMRX vs ABEO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABEO vs. IMRX, AMRN, QTTB, BCYC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Abeona Therapeutics Inc. (ABEO) ranks #673 by composite RQD confidence (39/100, grade D-) and #540 by equity capitalization ($260.8M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with ABEO at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABEO
ACTIVE
Abeona Therapeutics Inc. | D- | 39/100 | — | 73.7% | -35.0% | +0.22% | $260.8M | Benchmark Subject |
| IMRX Immuneering Corporation (Class A) | D | 45/100 | — | — | -35.0% | +0.75% | $260.1M | /imrx-vs-abeo → |
| AMRN Amarin Corporation plc | D- | 43/100 | — | 56.6% | -12.2% | -0.08% | $262.8M | /amrn-vs-abeo → |
| QTTB Q32 Bio Inc. | C- | 61/100 | 8.9x | — | 85.0% | -2.10% | $264.1M | /qttb-vs-abeo → |
| BCYC Bicycle Therapeutics plc | E | 24/100 | — | — | -35.0% | -1.55% | $267.4M | /bcyc-vs-abeo → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318306In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abeona Therapeutics Inc. (ABEO) reported GAAP revenue of $5.8M (N/A vs. FY2024 revenue of $0 , and +66.3% cumulative change since FY2023) , GAAP net income of -$71.2M, operating cash flow of -$76.3M, and free cash flow of -$84.3M (-44.2% YoY). On the balance sheet, ABEO closed FY2025 with $219.6M in total assets against $7.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $5.8M | -$71.2M | -$76.3M | -$84.3M | $219.6M | $7.8M |
| FY2024 (FY) | 2024-12-31 | $0 | $63.7M | -$56.0M | -$58.5M | $108.9M | $13.0M |
| FY2023 (FY) | 2023-12-31 | $3.5M | $54.2M | -$37.0M | -$37.0M | — | — |
3. ABEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Abeona Therapeutics Inc. (NASDAQ: ABEO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.56 (+0.22% 1D, market cap $260.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABEO ranks #673 in composite RQD confidence.
How does ABEO compare to IMRX and AMRN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABEO carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 73.7%, and ROIC of -35.0%. By comparison, IMRX (Immuneering Corporation (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $260.1M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABEO?
Per ABEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318306), Abeona Therapeutics Inc. generated $5.8M in revenue, -$71.2M in net income, and -$84.3M in free cash flow against $219.6M in total assets and $7.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABEO trading relative to its 50-day, 200-day, and 52-week technical levels?
ABEO last traded at $4.56 (+0.22% on volume of 874,347 shares), positioning the stock -12.98% below its 50-day simple moving average ($5.24) and -16.94% below its 200-day simple moving average ($5.49). Across its 52-week range of $4.00 to $7.65, ABEO sits at the 15.3% percentile with a 14-day RSI of 36.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($4.11 to $5.01).
ABEO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ABEO stock moving today?
Why ABEO Stock advanced +0.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.